SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Central Brain Tumor Registry ofthe United States (CBTRUS). 2002 tables. Available at URL: http://www.cbtrus.org/2002tables2002_18.htm [accessed January 28, 2004].
  • 2
    SEER Public-Use 1973–2001. Surveillance, Epidemiology, and End Results (SEER) Program Public Use Data (1973–2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch.
  • 3
    Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histologic subtype: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg. 1998; 88: 110.
  • 4
    Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy M. The conditional probability of survival of patients with primary malignant brain tumors. Cancer. 1999; 85: 485491.
  • 5
    Olson J, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000; 54: 14421448.
  • 6
    Peraud A, Ansari H, Bise K, et al. Clinical outcome of supratentorial astrocytoma WHO grade II. Acta Neurochir. 1998; 140: 12131222.
  • 7
    Piepmeier J, Christopher S, Spencer D, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery. 1996; 38: 872879.
  • 8
    Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. Neuro-oncol. 1998; 40: 153160.
  • 9
    Davis FG, McCarthy BJ, Berger MS. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. Neuro-oncol. 1999; 1: 205211.
  • 10
    Cox DR. Regression models and life tables. J R Stat Soc[B]. 1972; 34: 187202.
  • 11
    SAS Institute Inc. SAS/STAT user's guide, version 6, 4th ed, volume 1. Cary, NC: SAS Institute Inc., 1989.
  • 12
    Castillo MS, Davis FG, Surawicz T, et al. Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems. Neuroepidemiol. 2004; 23: 8593.
  • 13
    Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998; 90: 14731479.
  • 14
    van den Bent MJ. Advances in the biology and treatment of oligodendrogliomas. Cur Opin Neurol. 2004; 17: 675680.
  • 15
    Keles GE, Lambern KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of the extent of resection as a factor influencing outcome. J Neurosurg. 2001; 95: 735745.
  • 16
    Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005; 103: 12271233.
  • 17
    Black PM, Alexander E III, Martin C, et al. Craniotomy for tumor treatment in an intraoperative magnetic resonance imaging unit. Neurosurgery. 1999; 45: 423433.
  • 18
    Lipson AC, Gargolio PC, Black PM. Intraoperative magnetic resonance imaging: considerations for the operating room of the future. J Clin Neuroscience. 2001; 8: 305310.
  • 19
    Nicolato A, Gerosa MA, Fina P, et al. Prognostic factors in low-grade supratentorial astrocytomas: a multivariate statistical analysis in 76 surgically treated adult patients. Surg Neurol. 1995; 44: 208223.
  • 20
    North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer. 1990; 66: 614.
  • 21
    Scerrati M, Roselli R, Iacoangeli M, et al. Prognostic factors in low-grade (WHO II) gliomas of the cerebral hemispheres: the role of surgery. J Neurol Neurosurg Psychiat. 1996; 61: 291296.
  • 22
    Shaw EG, Scheithauer BW, O'Fallon JR. Supratentorial glioma: a comparative study by grade and histologic subtype. J Neurooncol. 1997; 31: 273278.
  • 23
    Trantakis C, Winkler D, Lindner D, et al. Clinical results in MR-guided therapy for malignant gliomas. Acta Neurochir. 2002; 85: 6571.
  • 24
    Whitton AC, Bloom HJG. Low-grade gliomas of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int J Radiat Oncol Biol Phys. 1990; 18: 783786.
  • 25
    Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 9971003.
  • 26
    Okcu MF, Selvan M, Wang LE, et al. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clinical Cancer Res. 2004; 10: 26182625.